{'fraction_non_alphanumeric': 0.018830525272547076, 'fraction_numerical': 0.0, 'mean_word_length': 5.644736842105263, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Unusual infections and development in the use of existing antimicrobial agents

New and unusual pathogens continue to cause infection in the immunocompromised patient, although common organisms still predominante. Protozoal infections are usually lethal, but infrequent, posing a dilemma as to who should receive prophylaxis and when. Infections caused by both common and rare bacteria, however, can be treated successfully in the vast majority of cases, making the need for prophylaxis less compelling. Viral infections are usually self-limiting, although those due to cytomegalovirus are sufficiently life threatening to make pre-emptive or early therapy necessary. By making the most of the limited diagnostic measures at our disposal and the finite number of antifungal agents available (the efficacy of which might be imporved by giving granlocyte-macrphage colony stimulating factor adjunctively), this approach may prove the most effective in managing deep-seated fungal infections involving the mould.